Calithera Presents Data Highlighting Discovery of Novel Series of Promising Synthetic Lethal Compounds
Findings presented today at AACR Annual Meeting detail Calithera discovery of VPS4A inhibitors and their…
News
Checkmate Pharmaceuticals Presents Clinical Trial Biomarker Data with Vidutolimod at the 2022 American Association for Cancer Research (AACR) Annual Meeting
CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) — Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company…
Adaptimmune Presents MAGE-A4 Expression Data from its Screening Protocol at AACR Confirming Expression Across a Broad Range of Solid Tumors
– Data from multiple solid tumor indications confirms that MAGE-A4 is a broadly expressed cancer…
iOnctura Presents Data at AACR Demonstrating its Unique Mechanism of Action for Clinical Stage ATX Inhibitor IOA-289
GENEVA, Switzerland, April 08, 2022 (GLOBE NEWSWIRE) — iOnctura SA, a clinical-stage oncology company targeting…
Agenus Presents Data on AGEN1571 (anti-ILT2) at AACR and Announces IND Clearance
First data presentation on AGEN1571 shows strong adaptive and innate immune responses Preclinical data indicate…
Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer
– Late-breaking presentation at AACR demonstrates potential to significantly delay onset of drug resistance to…
iTeos Presents New Data for Anti-TIGIT Antibody, EOS-448/GSK4428859A, at the AACR Annual Meeting 2022
Treatment with EOS-448 results in a decrease of TIGIT-positive cells in tumor biopsies, the first…
Senti Bio Presents New Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at AACR Annual Meeting
– Preclinical data demonstrate the use of gene circuits to improve the therapeutic potential of…
Oncorus Presents Preclinical Data on ONCR-021 and ONCR-788 Supporting Selectively Self-Amplifying vRNA Immunotherapy Platform at AACR Annual Meeting
– ONCR-021 and ONCR-788 demonstrate robust preclinical anti-tumor efficacy following IV-administration – – vRNA Immunotherapy…
Editas Medicine Reports Engineered iNK Cell Preclinical Data at American Association for Cancer Research Annual Meeting
Preclinical data demonstrate that edited iNK cells result in increased persistence, enhanced anti-tumor activity and…
Tempest Presents Promising Preclinical Data on Two Oncology Programs at the 2022 AACR Annual Meeting
Anti-tumor data from systemic novel TREX1 inhibitors designed to activate the STING pathway selectively in…
Rubius Therapeutics Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activity and Favorable Tolerability
Best Responses Include Partial Responses in Certain Patients with Non-Small Cell Lung Cancer, Metastatic Anal…
Anaveon presents compelling data from the Phase I/II study of ANV419 during the AACR Annual Meeting 2022
– ANV419 is very well-tolerated and demonstrates exceptional safety with strong pharmacodynamic effects and excellent…
Nykode Therapeutics announces presentation of preclinical data from its second generation Vaccibody vaccine technology at 2022 American Association for Cancer Research (AACR) Annual Meeting
OSLO, Norway, April 08, 2022 (GLOBE NEWSWIRE) — Nykode Therapeutics AS (Euronext Growth (Oslo): NYKD),…
Codiak’s exoASO™-C/EBPβ Demonstrates Significant Systemic Anti-Tumor Activity via Targeting Immune-Suppressive Myeloid Cells
– New preclinical data presented at AACR Annual Meeting 2022 – – Intravenous exosome candidate…
Monte Rosa Therapeutics Presents Preclinical Data Highlighting Potential of GSPT1-directed Molecular Glue Degrader MRT-2359 to Target Myc-driven Cancers at AACR Annual Meeting 2022
– Data Highlight Essential Role of GSPT1 in Sustaining Myc-induced Translational Addiction in Solid Tumors…
Zentalis Pharmaceuticals Announces Positive Initial Clinical Data on ZN-c3, its Wee1 Inhibitor, in Patients with Advanced Ovarian Cancer at AACR
ZN-c3 in combination with chemotherapy demonstrated strong anti-tumor activity in a heavily pretreated population, with…
C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader
– Single Agent CFT7455 Induces Deep and Durable Degradation of IKZF1/3 and Meaningful Decreases in…
Biomea Fusion Reports Preclinical Data on BMF-219 and Trial in Progress Presentations at AACR 2022 Annual Meeting
Covalent menin inhibitor BMF-219 showed strong cytotoxic activity as a single agent at similar concentrations across…
Theratechnologies Presents New In Vivo TH1902 Preclinical Data Demonstrating Tumor Growth Inhibition of Human Cancer Stem-Like Cells (CD133+) in Both Triple-Negative Breast and Ovarian Cancers AACR Annual Meeting 2022
Two Additional Preclinical Proof-of-concept Posters in Ovarian and Metastatic Lung Cancer Models Also Presented at…